HAP

CPP Announces Acquisition of Canoga Park Apartments in Los Angeles, California

Retrieved on: 
Thursday, May 2, 2024
Education, Partner, Housing, CPP, Health, HAP, Partnership, Federal, AMI, Lighting, Acquisition, Community, WNC, HVAC

LOS ANGELES, May 02, 2024 (GLOBE NEWSWIRE) -- CPP (Community Preservation Partners), a mission-driven affordable housing preservation developer has announced the acquisition and planned renovation of Canoga Park Apartments, an affordable housing development in Los Angeles, Calif.

Key Points: 
  • LOS ANGELES, May 02, 2024 (GLOBE NEWSWIRE) -- CPP (Community Preservation Partners), a mission-driven affordable housing preservation developer has announced the acquisition and planned renovation of Canoga Park Apartments, an affordable housing development in Los Angeles, Calif.
  • This is the fifth community in the greater Los Angeles area for CPP and the 60th in the state.
  • Built in 1983, Canoga Park Apartments is comprised of 14 walk-up units across three stories, the first of which is tuck-under parking.
  • “WNC is pleased to partner with CPP to renew affordability status for Canoga Park Apartments,” said Anil Advani, Executive Vice President of Originations and Finance at WNC.

CPP and WNC & Associates Announce Acquisition of Affordable Housing Community in El Centro, Calif.

Retrieved on: 
Thursday, April 18, 2024
Education, GED, Common, Partner, Housing, CPP, Health, HAP, Paint, Partnership, Trust, AMI, Section 8, Senior counsel, Mental health, LED, Acquisition, Community, WNC, HVAC, California Bank and Trust, Real estate

EL CENTRO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- CPP (Community Preservation Partners), a mission-driven affordable housing preservation developer, and WNC & Associates (WNC), a family-owned business known as both a pioneer and leader in the affordable housing industry, have announced the acquisition and planned renovation of Euclid Villas in El Centro, Calif..

Key Points: 
  • EL CENTRO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- CPP (Community Preservation Partners), a mission-driven affordable housing preservation developer, and WNC & Associates (WNC), a family-owned business known as both a pioneer and leader in the affordable housing industry, have announced the acquisition and planned renovation of Euclid Villas in El Centro, Calif..
  • The acquisition is in partnership with Bettencourt Properties, Inc. and The Beneficial Housing Foundation.
  • “WNC is proud to partner with CPP on another affordable housing project,” said Anil Advani, Executive Vice President of Originations and Finance at WNC.
  • “When addressing affordable housing needs in communities, it is important to look beyond the physical needs of the property.

World View Expands into Indo-Pacific with $25M Strategic Investment

Retrieved on: 
Thursday, May 2, 2024
Air, Transport, Aerospace, Manufacturing, University of Melbourne, HAP, Partnership, Research, University, Engineering, Indo-Pacific, SNC, Multimedia, Worldview

View the full release here: https://www.businesswire.com/news/home/20240430194762/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240430194762/en/
    World View's Stratollite system, a stratospheric high-altitude platform (HAP), is prepared to launch from Page, Arizona.
  • (Photo: Business Wire)
    The strategic investment from Breakthrough Victoria will enable World View to establish a regional Indo-Pacific headquarters in Melbourne.
  • The Indo-Pacific business will operate as World View Indo-Pacific, a wholly owned subsidiary that will allow World View to pursue new customers and access new markets while benefitting from local talent, technology and capital.
  • This investment is part of World View’s recently announced multi-close strategic Series D funding round, led by SNC, that saw participation from both new and existing investors.

Penn Highlands Healthcare Urges the Community: Help Save Lives. Become an Organ Donor

Retrieved on: 
Thursday, April 11, 2024
Kidney disease, Cancer, Lupus nephritis, Kidney, Hospital, Transplant, Travel, Nausea, Cardiology, HAP, Surgeon, DuBois, Pennsylvania, Life, Friends, Autoimmune disease, Family, Nursing, Eye, Dialysis, DLA, Social, Lupus, Quality of life, Pharmacist, Dentistry

She cannot travel far from her dialysis provider as she awaits a donor kidney.

Key Points: 
  • She cannot travel far from her dialysis provider as she awaits a donor kidney.
  • Eight lives can be saved by one organ donor; and, one tissue donor can heal 75 lives.
  • You can help people like Lisa who are waiting for an organ, eye or tissue donation by becoming a donor.
  • You can also become a donor when you renew your driver’s license in person, or online at dmv.pa.gov .

Atlantic Radiology New Hampshire contracts with Healthcare Administrative Partners for Comprehensive Revenue Cycle and Practice Management Services

Retrieved on: 
Thursday, April 25, 2024
Professional Services, Health, Hospitals, Practice Management, Health Insurance, Radiology, Outsourcing Business, Practice management, HAP, MD, Partner, Knowledge, Hospital

Healthcare Administrative Partners (HAP), a leading provider of outsourced billing, coding, and practice management solutions for radiology practices, today announces the addition of Atlantic Radiology New Hampshire in Portsmouth, NH to its roster of radiology revenue cycle and practice management clients.

Key Points: 
  • Healthcare Administrative Partners (HAP), a leading provider of outsourced billing, coding, and practice management solutions for radiology practices, today announces the addition of Atlantic Radiology New Hampshire in Portsmouth, NH to its roster of radiology revenue cycle and practice management clients.
  • Under the terms of the agreement, HAP will perform all core revenue cycle services on behalf of Atlantic Radiology New Hampshire including billing, coding, carrier credentialing, business intelligence, and MIPS Measure Assurance Services.
  • HAP will also provide the group with comprehensive practice management services.
  • HAP impressed us with their extensive knowledge of revenue cycle and practice management and commitment to superior customer service.

European Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment Options

Retrieved on: 
Monday, April 22, 2024
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mortality, Urinary tract infection, Pyelonephritis, WHO, News, World Health Organization, Safety, Infection, European Commission, Bacteria, Inc., AMR, Aztreonam, HAP, Fungal infection, VAP, Hospital-acquired pneumonia, Gram-negative bacteria, Patient, PFE, Ventilator-associated pneumonia, Parasitism, Multiple drug resistance, Virus, Civil service commission, Fungus, Antimicrobial resistance, Head, Disease, Gram, Vaccine

(NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.

Key Points: 
  • (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary tract infections (cUTI), including pyelonephritis.
  • It is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options.
  • “For healthcare teams treating patients with serious Gram-negative bacterial infections, the prospect of running out of effective treatment options is a daunting but very real threat,” said Yehuda Carmeli, Head, National Institute for Antibiotic Resistance and Infection Control, Tel Aviv Medical Center, Israel, and an investigator in the REVISIT study.
  • Marketing authorization applications for EMBLAVEO are planned for submission in other countries.

Health Village Imaging, LLC Selects Healthcare Administrative Partners as Comprehensive Revenue Cycle Management Services Provider

Retrieved on: 
Tuesday, April 9, 2024
Health, Technology, Photography, Health Technology, Practice Management, Radiology, Partner, MRI, Practice management, Partnership, Patient, HVI, HAP, Property management

Healthcare Administrative Partners (HAP), a leading provider of outsourced billing, coding, and practice management solutions for radiology practices, today announces the addition of Health Village Imaging , LLC (HVI) to its roster of radiology revenue cycle management clients.

Key Points: 
  • Healthcare Administrative Partners (HAP), a leading provider of outsourced billing, coding, and practice management solutions for radiology practices, today announces the addition of Health Village Imaging , LLC (HVI) to its roster of radiology revenue cycle management clients.
  • Health Village Imaging is a full-service imaging center offering medical imaging services across central and southern New Jersey.
  • Under the terms of the agreement, HAP will perform all core revenue cycle services on behalf of Health Village Imaging including billing, coding, carrier credentialing, business intelligence, and MIPS Measure Assurance Services.
  • We are happy to expand upon our long-term relationship with Coastal Imaging by servicing Health Village Imaging’s revenue cycle management needs.”

Audubon Launches Unprecedented Vapor Recovery & Reuse System for EPA Compliance

Retrieved on: 
Tuesday, March 26, 2024
Packaging, Engineering, Chemicals, Plastics, Other Energy, Oil, Gas, Manufacturing, Energy, Ethanol, Gasoline, VUS, EPA, Volatile organic compound, NESHAP, CFR, Atmosphere, EPC, HAP

The unprecedented VUS advances vapor recovery functions by not only ensuring compliance with Environmental Protection Agency (EPA) regulations—it transforms toxic waste emissions into power or heat energy.

Key Points: 
  • The unprecedented VUS advances vapor recovery functions by not only ensuring compliance with Environmental Protection Agency (EPA) regulations—it transforms toxic waste emissions into power or heat energy.
  • The proprietary system captures waste vapor emissions according to new, stricter federal regulations and reuses them as an energy source.
  • Unlike traditional methods that merely remove waste vapor, the VUS converts it for power generation, electrical grid support, or renewable feedstock.
  • Audubon will work with its energy and industrial clients to support compliance with these standards for applications such as terminal loading, marine loading, fuel storage, and ethanol production, among others.

World View Secures Strategic Series D Funding Led by SNC

Retrieved on: 
Tuesday, February 27, 2024
Public Policy, Government, Defense, Other Defense, Finance, Professional Services, Homeland Security, Aerospace, Manufacturing, HAP, NOAA, Multimedia, United States Air Force, SNC, NASA, ISR, Aviation, IAS, Series, Boeing, Worldview, Security, Altitude, Partnership, Management

World View, a global leader in stratospheric exploration and flight, announces the successful opening and initial funding of a Series D round.

Key Points: 
  • World View, a global leader in stratospheric exploration and flight, announces the successful opening and initial funding of a Series D round.
  • (Photo: Business Wire)
    This strategic investment builds upon the multi-year strategic partnership initiated in 2022 between World View and SNC.
  • As part of the Series D funding round, two notable individuals join the World View Board of Directors.
  • “SNC is committed to quality and excellence in performance, and we look forward to enhancing this much-needed capability in coordination with World View."

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024

Retrieved on: 
Sunday, February 4, 2024
Civil service commission, Pneumonia, Febrile neutropenia, Eli Lilly, Triprolidine, International, Bacteria, Schizophrenia, Myelopathy, Incidence, ALD, Cefepime, Allergic rhinitis, Nasal congestion, Neutrophil, Agency, COMP, Fever, HAP, EEIG, Headache, Static pressure, Medicine, Committee, Conditional, Spinal cord, Hospital-acquired pneumonia, PTC, Neutropenia, Public, CHMP, European, AMD, Patient, Diagnosis, Marketing, RCVS, European Commission, Brain, Disease, Infection, Inflammation, Male, PRES, PRAC, Pain, Pyelonephritis, Urinary tract infection, VAP, Ageing, EMA, Geographic atrophy, Adrenoleukodystrophy, Therapy, News, INN, Duchenne muscular dystrophy, Common, Fungal infection, Vaccine

Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.

Key Points: 
  • Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.
  • Ltd. Marketing-authorisation holderVarious companiesMore informationSynapse